Literature DB >> 25223832

Killing without collateral damage: new hope for sepsis therapy.

Alastair G Proudfoot1, Charlotte Summers2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25223832      PMCID： PMC4206516          DOI： 10.1038/icb.2014.73

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN： 0818-9641            Impact factor:   5.126


× No keyword cloud information.
  9 in total

Review 1.  Targeting signal transduction as a strategy to treat inflammatory diseases.

Authors:  Luke A J O'Neill
Journal:  Nat Rev Drug Discov       Date:  2006-06-09       Impact factor: 84.694

Review 2.  Severe sepsis and septic shock.

Authors:  Derek C Angus; Tom van der Poll
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

3.  Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.

Authors:  Gordon R Bernard; Bruno Francois; Jean-Paul Mira; Jean-Louis Vincent; R Phillip Dellinger; James A Russell; Steven P Larosa; Pierre-Francois Laterre; Mitchell M Levy; Wayne Dankner; Nicola Schmitt; Justin Lindemann; Xavier Wittebole
Journal:  Crit Care Med       Date:  2014-03       Impact factor: 7.598

4.  Drotrecogin alfa (activated) in adults with septic shock.

Authors:  V Marco Ranieri; B Taylor Thompson; Philip S Barie; Jean-François Dhainaut; Ivor S Douglas; Simon Finfer; Bengt Gårdlund; John C Marshall; Andrew Rhodes; Antonio Artigas; Didier Payen; Jyrki Tenhunen; Hussein R Al-Khalidi; Vivian Thompson; Jonathan Janes; William L Macias; Burkhard Vangerow; Mark D Williams
Journal:  N Engl J Med       Date:  2012-05-22       Impact factor: 91.245

5.  Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients.

Authors:  A Kiani; A Tschiersch; E Gaboriau; F Otto; A Seiz; H P Knopf; P Stütz; L Färber; U Haus; C Galanos; R Mertelsmann; R Engelhardt
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

6.  A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis.

Authors:  Peter Kruger; Michael Bailey; Rinaldo Bellomo; David James Cooper; Meg Harward; Alisa Higgins; Belinda Howe; Darryl Jones; Chris Joyce; Karam Kostner; John McNeil; Alistair Nichol; Michael S Roberts; Gillian Syres; Bala Venkatesh
Journal:  Am J Respir Crit Care Med       Date:  2013-04-01       Impact factor: 21.405

Review 7.  Role of Toll-like receptor responses for sepsis pathogenesis.

Authors:  Heike Weighardt; Bernhard Holzmann
Journal:  Immunobiology       Date:  2007-11-26       Impact factor: 3.144

Review 8.  Critical care and the global burden of critical illness in adults.

Authors:  Neill K J Adhikari; Robert A Fowler; Satish Bhagwanjee; Gordon D Rubenfeld
Journal:  Lancet       Date:  2010-10-11       Impact factor: 79.321

9.  MPLA inhibits release of cytotoxic mediators from human neutrophils while preserving efficient bacterial killing.

Authors:  Marie-Hélène Ruchaud-Sparagano; Ross Mills; Jonathan Scott; A John Simpson
Journal:  Immunol Cell Biol       Date:  2014-07-08       Impact factor: 5.126
  9 in total
  1 in total

1.  In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A.

Authors:  Delphine Guldner; Julianne K Hwang; Maria Clara D Cardieri; Meaghan Eren; Parissa Ziaei; M Grant Norton; Cleverson D Souza
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.